PARP Inhibitor Biomarkers Market Report Scope & Overview:
PARP Inhibitor Biomarkers Market was valued at USD 901.25 million in 2023 and is expected to reach USD 1892.80 million by 2032, growing at a CAGR of 8.64% from 2024-2032.
The PARP Inhibitor Biomarkers Market Report provides distinctive insight by concentrating on the prevalence and incidence of BRCA1/2 and HRD mutations and how they propel biomarker-directed diagnostics. The report explores the trends in PARP inhibitor prescription by geography through an analysis of regulatory effects and availability. It also explores the volume trends for biomarker testing between 2020 and 2032 in response to increases in diagnostic adoption. Furthermore, it offers an in-depth evaluation of R&D expenditure on biomarker testing with a focus on innovation. Finally, the report examines healthcare expenditures on genomic testing, assessing reimbursement models through government, commercial, private, and out-of-pocket channels. Such insights provide an all-encompassing market knowledge beyond typical growth analysis.
The U.S. leads the North America PARP Inhibitor Biomarkers Market with 8.49% CAGR because of its high precision medicine adoption rates, robust regulatory approvals, and heavy investments in R&D for biomarker-based oncology therapies. Also, favorable reimbursement policies and the availability of major market players drive the adoption of biomarker testing, especially for BRCA and HRD mutations in cancer diagnosis.
Market Dynamics
Drivers
Rising Adoption of Precision Medicine in Oncology is accelerating the market growth.
The mounting focus on precision medicine is a major growth driver for the PARP Inhibitor Biomarkers Market, as biomarker-based therapies enhance treatment effectiveness and patient survival. The mounting incidence of cancers, including breast, ovarian, and prostate cancer, has fueled the demand for biomarker testing, especially for BRCA1/2 and homologous recombination deficiency (HRD). Based on the American Cancer Society (2023), an estimated 297,790 new breast cancer cases were diagnosed in the U.S., which is a clear indication of the need for targeted treatments. Recent breakthroughs, including Roche's Elecsys PARP Inhibitor Biomarker Test (March 2023) and QIAGEN's QIAseq Platform Partnership (March 2023), further strengthen the market growth. The combination of next-generation sequencing (NGS) and companion diagnostics in oncology is promoting the use of PARP inhibitor biomarker testing, cementing its position as part of personalized cancer therapy.
Expanding clinical applications of PARP inhibitors are propelling the market to grow.
Biomarker testing demand is driven by the growth of clinical indications for PARP inhibitors from ovarian and breast cancer to prostate and pancreatic cancer. In 2023, the FDA approved the indication of rucaparib in BRCA-mutated prostate cancer, an important milestone for the market. As reported by the National Cancer Institute (NCI), prostate cancer was the second leading cancer in men, with more than 288,300 new cases in the United States in 2023. Pharmaceutical companies like AstraZeneca and Merck are carrying out clinical trials to test PARP inhibitors in combination with immunotherapies and other targeted therapies. The growing clinical use of HRR and HRD testing also plays a significant role in promoting the routine use of PARP inhibitor biomarkers, which are crucial in cancer treatment decisions and management.
Restraint
High costs and limited accessibility of biomarker testing are restraining the market growth.
One of the significant constraints in the PARP Inhibitor Biomarkers Market is the elevated cost and reduced availability of biomarker testing, especially in low- and middle-income countries (LMICs). Next-generation sequencing (NGS) and companion diagnostics (CDx) tests employed to identify BRCA mutations, HRD, and HRR are costly, with the cost of testing ranging between USD 2,000 and USD 5,000 per patient. Moreover, insurance for biomarker testing is not uniform, and hence, it is out of reach for most patients, particularly those with no complete healthcare plans. The World Health Organization (WHO) report identifies inequities in access to precision diagnostics, where sophisticated biomarker testing is more common in North America and Europe compared to Asia-Pacific or Latin America. The absence of standardized testing protocols, regulatory barriers, and reimbursement issues also constricts market growth, preventing extensive use in clinical oncology.
Opportunities
The PARP Inhibitor Biomarkers Market is a large opportunity with the increased adoption of companion diagnostics (CDx) and personalized medicine.
With regulatory bodies such as the FDA and EMA placing focus on biomarker-guided therapy approvals, demand for HRD, BRCA1/2, and HRR testing is on the rise to inform PARP inhibitor treatment. This is further transforming the market with the advent of liquid biopsy technology, providing non-invasive test solutions to monitor tumor development and drug reaction in real-time. Moreover, joint ventures between pharmaceutical companies and biotech companies are transforming predictive biomarker assays and broadening clinical trial entry criteria for patients from conventional genetic markers. As oncology treatment evolves toward personalized therapy, biomarker-driven drug development will continue to gain momentum, creating new revenue streams for diagnostic developers and pharma players.
Challenges
One of the key challenges in the PARP Inhibitor Biomarkers Market is the absence of global standardization for biomarker testing and regulatory clearances.
Regions have different requirements for biomarker validation, creating roadblocks for companies introducing companion diagnostics (CDx) and next-generation sequencing (NGS)-based assays globally. For instance, while the FDA requires rigorous clinical validation, other countries have less standardized guidelines, and hence, test accuracy and reliability may vary. Delays in regulatory approvals also hamper the implementation of new biomarker-based therapies, which reduces oncologists' confidence in prescribing PARP inhibitors. The European Society for Medical Oncology (ESMO) report emphasizes the necessity of harmonized biomarker testing frameworks to enhance clinical outcomes. Lacking clear regulatory channels and normalized biomarker interpretation, the commercialization of sophisticated diagnostic solutions is an obstacle to market expansion.
Segmentation Analysis
By Product
The Kits segment dominated the PARP Inhibitor Biomarkers Market with a 66.12% market share in 2023 because of its simplicity, standardized protocols, and extensive use in clinical and research environments. These kits provide pre-validated reagents, controls, and streamlined workflows, facilitating effective detection of biomarkers like BRCA1/2, HRD, and HRR mutations critical to PARP inhibitor therapy guidance. The growing incorporation of companion diagnostics (CDx) for individualized treatment approaches has also driven demand for readily available test kits commercially. FDA-approved and CE-marked approvals of test kits by dominant players like Myriad Genetics and QIAGEN have strengthened market penetration. Furthermore, growth in hospital-based and reference lab testing has entrenched ready-to-use kit dominance and ensured consistent and precise biomarker measurement in oncology.
The Assays segment is expected to grow the fastest over the forecast years, fueled by innovation in next-generation sequencing (NGS) and liquid biopsy technology. In contrast to traditional kits, assay-based testing provides greater sensitivity, multiplex detection, and more profound genomic information, which is making it more popular in precision oncology research and clinical use. The growth in integrated biomarker panels, such as HRD and DDR pathway analysis, has continued to fuel the need for individualized assay solutions. Further, biopharma partnerships with diagnostics companies for creating individualized assays for drug discovery have helped in accelerating innovation. The movement toward real-time and high-throughput screening techniques in oncology-based molecular diagnostic laboratories is poised to fuel increased uptake of assay-based biomarker detection, stimulating significant market growth during the next few years.
By Services
The BRCA 1 & 2 Testing segment dominated the PARP Inhibitor Biomarkers Market, with a 44.58% market share in 2023, mainly because it plays a pivotal role in determining patients who can be treated with PARP inhibitor treatments. Mutations of BRCA1 and BRCA2 are major predictive biomarkers for several cancers, such as breast, ovarian, prostate, and pancreatic cancer, resulting in widespread clinical use. Regulatory agencies such as the FDA and EMA have cleared numerous BRCA-based companion diagnostics (CDx), including Myriad Genetics' BRACAnalysis CDx and QIAGEN's therascreen BRCA1/2 RGQ PCR Kit, further cementing their place in personalized medicine. Furthermore, the increasing incidence of hereditary cancer syndromes and greater recommendations by groups such as the NCCN and ASCO have fueled demand for BRCA testing. The increasing integration of BRCA screening into initial cancer risk evaluation programs has also helped it maintain market dominance.
By Application
The Breast Cancer segment dominated the PARP Inhibitor Biomarkers Market with around 50.12% market share in 2023 because of the widespread prevalence of breast cancer, especially BRCA1/2-mutated breast cancer, which responds significantly to PARP inhibitor treatment. PARP inhibitors like Olaparib (Lynparza) and Talazoparib (Talzenna), receiving FDA approvals for HER2-negative metastatic breast cancer with BRCA mutations, have increased biomarker testing demand even more. Companies like NCCN and ASCO suggest BRCA1/2 testing for patients with breast cancer, which is boosting the clinical usage of PARP inhibitor biomarkers. Moreover, developments in liquid biopsy as well as companion diagnostics have improved access and precision in the identification of BRCA mutations in breast cancer patients, driving the segment's market leadership. The increasing recognition of inherited breast cancer syndromes and the inclusion of genetic testing in treatment protocols have also further entrenched breast cancer as the top product in the market.
The Ovarian Cancer segment will be the fastest-growing segment with 9.30% CAGR throughout the forecast period in the PARP Inhibitor Biomarkers Market because of robust clinical evidence for the effectiveness of PARP inhibitors for the treatment of BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancer. PARP inhibitor approvals as first-line and maintenance therapies for ovarian cancer for Olaparib, Niraparib (Zejula), and Rucaparib (Rubraca) have hugely widened the number of eligible patients based on biomarker analysis. Evidence, such as in the PRIMA and SOLO-1 trials, has established benefit for progression-free survival (PFS) with PARP inhibitors and contributed to uptake. Additionally, programs such as universal genetic testing for patients with ovarian cancer, endorsed by groups such as ESMO and SGO, have enhanced early biomarker detection rates. With an increasing incidence of ovarian cancer and better diagnostic technologies, this segment will witness high growth.
Regional Analysis
North America dominated the PARP inhibitor biomarkers market with a 44.08% market share in 2023 due to a well-developed healthcare infrastructure, extensive adoption of precision medicine, and robust regulatory environments favoring biomarker-based therapies. The region is favored by high research investments, large-scale clinical trials, and business partnerships between biotech players and pharma giants to improve biomarker-based cancer therapy. Also, positive payment policy and strong awareness among healthcare providers towards genetic testing for BRCA and HRD mutations drive market leadership. Major players like Roche, Myriad Genetics, and QIAGEN make the presence of the region stronger in leadership.
Europe is experiencing the fastest growth in the PARP Inhibitor Biomarkers Market with 9.49% CAGR throughout the forecast period due to growing cancer prevalence, enhanced government support for precision medicine, and increased access to genomic testing. Germany, the UK, and France are making significant investments in next-generation sequencing (NGS) and biomarker-based therapies to enhance cancer diagnosis and treatment. In addition, partnerships among academic institutions, biotech companies, and regulatory bodies are driving clinical validation and uptake of PARP inhibitor biomarkers. Increasing recognition of personalized medicine, along with programs like the European Union's Beating Cancer Plan, is driving market growth, with Europe being the fastest-growing region.
Key Market Players
Myriad Genetics, Inc. (BRACAnalysis CDx, myChoice HRD)
NeoGenomics Laboratories (NeoTYPE Tumor Profiles, InVisionFirst-Lung)
Invitae Corporation (Invitae BRCA1/2 Test, Invitae Multi-Cancer Panel)
F. Hoffmann-La Roche Ltd. (AVENIO Tumor Tissue Analysis Kits, cobas EGFR Mutation Test)
QIAGEN N.V. (therascreen BRCA1/2 RGQ PCR Kit, GeneReader NGS System)
Thermo Fisher Scientific Inc. (Oncomine BRCA Assay, Ion AmpliSeq Cancer Hotspot Panel)
Illumina, Inc. (TruSight Tumor 170, VeriSeq Targeted Cancer Panel)
Agilent Technologies, Inc. (SureSelect XT HS2 DNA Kit, Dako Omnis)
Bio-Rad Laboratories, Inc. (QX200 Droplet Digital PCR System, BioPlex 2200 System)
PerkinElmer, Inc. (NEXTFLEX BRCA1/2 Panels, LabChip GX Touch)
Hologic, Inc. (Aptima HPV Assay, Panther Fusion System)
Abbott Laboratories (Vysis ALK Break Apart FISH Probe Kit, m2000 RealTime System)
Siemens Healthineers AG (Atellica Solution, Versant kPCR Molecular System)
Becton, Dickinson and Company (BD) (BD MAX System, BD Onclarity HPV Assay)
Genomic Health, Inc. (Oncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score)
Foundation Medicine, Inc. (FoundationOne CDx, FoundationOne Liquid CDx)
Guardant Health, Inc. (Guardant360, GuardantOMNI)
Caris Life Sciences (MI Exome, MI Transcriptome)
Natera, Inc. (Signatera, Prospera)
Pacific Biosciences of California, Inc. (Sequel II System, SMRTbell Express Template Prep Kit)
Suppliers (These suppliers provide essential reagents, assay kits, and sequencing consumables used in PARP inhibitor biomarker testing.)
Thermo Fisher Scientific
Merck KGaA
Agilent Technologies
Qiagen N.V.
Bio-Rad Laboratories, Inc.
PerkinElmer, Inc.
Roche Diagnostics
Illumina, Inc.
Becton, Dickinson and Company (BD)
Danaher Corporation
Recent Development
March 2023 – F. Hoffmann-La Roche Ltd. (Roche), a leading biotechnology company focused on pharmaceuticals and diagnostics for serious diseases, announced a partnership with Eli Lilly and Company to accelerate the development of Roche's Elecsys PARP Inhibitor Biomarkers.
March 2023 – QIAGEN N.V. launched its new QIAseq Platform Partnership program. The initial partnership under the program is with medical data-analysis solution provider SOPHiA GENETICS, combining QIAGEN's QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform to power more accurate precision medicine solutions
| Report Attributes | Details |
| Market Size in 2023 | US$ 901.25 million |
| Market Size by 2032 | US$ 1892.80 million |
| CAGR | CAGR of 8.64% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Kits, Assays) • By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others) • By Application (Breast Cancer, Ovarian Cancer, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Myriad Genetics, Inc., NeoGenomics Laboratories, Invitae Corporation, F. Hoffmann-La Roche Ltd., QIAGEN N.V., Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Hologic, Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Genomic Health, Inc., Foundation Medicine, Inc., Guardant Health, Inc., Caris Life Sciences, Natera, Inc., Pacific Biosciences of California, Inc., and other players. |
Ans: The PARP Inhibitor Biomarkers Market is expected to grow at a CAGR of 8.64% from 2024-2032.
Ans: The PARP Inhibitor Biomarkers Market was USD 901.25 million in 2023 and is expected to reach USD 1892.80 million by 2032.
Ans: Expanding clinical applications of PARP inhibitors are propelling the market to grow.
Ans: The “Kits” segment dominated the PARP Inhibitor Biomarkers Market.
Ans: North America dominated the PARP Inhibitor Biomarkers Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of BRCA1/2 and HRD Mutations (2023)
5.2 PARP Inhibitor Prescription Trends (2023), by Region
5.3 Biomarker Testing Volume, by Region (2020-2032).
5.4 Research and Development Investments in Biomarker Testing (2023-2032)
5.5 Healthcare Spending on Genomic Testing, by Region (Government, Commercial, Private, Out-of-Pocket) (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. PARP Inhibitor Biomarkers Market Segmentation, By Product
7.1 Chapter Overview
7.2 Kits
7.2.1 Kits Market Trends Analysis (2020-2032)
7.2.2 Kits Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Assays
7.3.1 Assays Market Trends Analysis (2020-2032)
7.3.2 Assays Market Size Estimates and Forecasts to 2032 (USD Million)
8. PARP Inhibitor Biomarkers Market Segmentation, By Services
8.1 Chapter Overview
8.2 BRCA 1 & 2 Testing
8.2.1 BRCA 1 & 2 Testing Market Trends Analysis (2020-2032)
8.2.2 BRCA 1 & 2 Testing Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 HRD Testing
8.3.1 HRD Testing Market Trends Analysis (2020-2032)
8.3.2 HRD Testing Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 HRR Testing
8.4.1 HRR Testing Market Trends Analysis (2020-2032)
8.4.2 HRR Testing Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Others
8.5.1 Other Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. PARP Inhibitor Biomarkers Market Segmentation, By Application
9.1 Chapter Overview
9.2 Breast Cancer
9.2.1 Breast Cancer Market Trends Analysis (2020-2032)
9.2.2 Breast Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Ovarian Cancer
9.3.1 Ovarian Cancer Market Trends Analysis (2020-2032)
9.3.2 Ovarian Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Others
9.4.1 Other Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.4 North America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.2.5 North America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.6.2 USA PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.2.6.3 USA PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.7.2 Canada PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.2.7.3 Canada PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.8.2 Mexico PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.2.8.3 Mexico PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.4 Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.5 Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.6.2 Poland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.6.3 Poland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.7.2 Romania PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.7.3 Romania PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.8.2 Hungary PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.8.3 Hungary PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.9 Turkey
10.3.1.9.1 Turkey PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.9.2 Turkey PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.9.3 Turkey PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.4 Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.5 Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.6.2 Germany PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.6.3 Germany PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.7.2 France PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.7.3 France PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.8.2 UK PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.8.3 UK PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.9.2 Italy PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.9.3 Italy PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.10.2 Spain PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.10.3 Spain PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.11.2 Netherlands PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.11.3 Netherlands PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.12.2 Switzerland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.12.3 Switzerland PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.13.2 Austria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.13.3 Austria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.4 Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.5 Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.6.2 China PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.6.3 China PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.7.2 India PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.7.3 India PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.8.2 Japan PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.8.3 Japan PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.9.2 South Korea PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.9.3 South Korea PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.10.2 Vietnam PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.10.3 Vietnam PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.11.2 Singapore PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.11.3 Singapore PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.12.2 Australia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.12.3 Australia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.4 Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.5 Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.6.2 UAE PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.6.3 UAE PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.7.2 Egypt PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.7.3 Egypt PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.9.2 Qatar PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.9.3 Qatar PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.4 Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.2.5 Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.6.2 South Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.2.6.3 South Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.7.2 Nigeria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.2.7.3 Nigeria PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.4 Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.6.5 Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.6.2 Brazil PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.6.6.3 Brazil PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.7.2 Argentina PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.6.7.3 Argentina PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.8.2 Colombia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.6.8.3 Colombia PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America PARP Inhibitor Biomarkers Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11. Company Profiles
11.1 Myriad Genetics, Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 NeoGenomics Laboratories
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Invitae Corporation
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 QIAGEN N.V.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Thermo Fisher Scientific Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Illumina, Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Agilent Technologies, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Bio-Rad Laboratories, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 PerkinElmer, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Product
By Services
By Application
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
The Human Papillomavirus (HPV) Vaccine Market size was USD 4.12 Billion in 2022 and is expected to Reach USD 10.64 Billion by 2030 and grow at a CAGR of 12.6% over the forecast period of 2023-2030.
Drainage bottles Market was valued at USD 508 million in 2023 and is expected to reach USD 884.07 million by 2032, growing at a CAGR of 6.36% over the forecast period of 2024-2032.
The Colposcope Market was valued at USD 392.10 million in 2023 and is expected to reach USD 593.35 million by 2032, growing at a CAGR of 4.73% over the forecast period of 2024-2032.
The Wireless Health Market Size was valued at USD 198.7 Billion in 2023 and is expected to reach USD 896.3 Billion by 2032, growing at a CAGR of 18.2% over the forecast period 2024-2032.
The Medical Aesthetics market size was USD 19.28 billion in 2023 and is expected to reach USD 56.41 billion by 2032 and grow at a CAGR of 12.67% over the forecast period of 2024-2032.
The Healthcare Logistics Market was valued at USD 88.04 billion in 2023 and is expected to reach USD 192.81 billion by 2032, growing at a CAGR of 9.07%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
